Palvella officer plans $651K stock sale

Officer Kathleen Goin filed a Rule 144 notice to sell 4,302 PVLA shares, following similar monthly sales of 4,302 shares over the prior three months.

Rhea-AI Filing Summary

PALVELLA THERAPEUTICS, INC. (PVLA) is the issuer of common stock that officer Kathleen Goin plans to sell under Rule 144. The notice covers a proposed sale of 4,302 shares of common stock through Piper Sandler & Co on Nasdaq on September 16, 2026, following a cash stock option exercise with Palvella as issuer.

Goin also reported prior Rule 144 sales of 4,302 shares of Palvella common stock on each of June 17, 2026, July 15, 2026, and August 19, 2026, with reported aggregate values in the hundreds of thousands of dollars for each transaction. Piper Sandler signed the notice as attorney-in-fact for Goin.

Key Figures

Proposed shares to be sold: 4,302 shares Approximate market value of proposed sale: $650,548.44 Shares sold June 17, 2026: 4,302 shares +5 more

8 metrics

Proposed shares to be sold 4,302 shares Common stock sale under Rule 144 planned for September 16, 2026

Approximate market value of proposed sale $650,548.44 Reported aggregate market value for 4,302 PVLA shares in the proposed Rule 144 sale

Shares sold June 17, 2026 4,302 shares Rule 144 sale of Palvella common stock by Kathleen Goin on June 17, 2026

Sale value June 17, 2026 $476,372.94 Aggregate value for 4,302 PVLA shares sold on June 17, 2026

Shares sold July 15, 2026 4,302 shares Rule 144 sale of Palvella common stock on July 15, 2026

Sale value July 15, 2026 $642,191.37 Aggregate value for 4,302 PVLA shares sold on July 15, 2026

Shares sold August 19, 2026 4,302 shares Rule 144 sale of Palvella common stock on August 19, 2026

Sale value August 19, 2026 $654,791.07 Aggregate value for 4,302 PVLA shares sold on August 19, 2026

Key Terms

Rule 144, stock option exercise, attorney-in-fact, common stock

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

stock option exercise financial

"Common Stock | 09/16/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

attorney-in-fact regulatory

"as attorney-in-fact for Kathleen Goin"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

common stock financial

"Common Stock | Piper Sandler & Co Inc"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for PALVELLA THERAPEUTICS, INC. (PVLA)?

It discloses that officer Kathleen Goin has filed a Rule 144 notice to sell 4,302 shares of Palvella Therapeutics common stock through Piper Sandler & Co on or about September 16, 2026, following a cash stock option exercise with the issuer.

How many PVLA shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 4,302 shares of PALVELLA THERAPEUTICS, INC. common stock. The shares are to be sold through Piper Sandler & Co on Nasdaq in connection with a stock option exercise paid in cash.

What prior PVLA share sales by Kathleen Goin are reported in the last three months?

The filing lists three prior Rule 144 sales, each of 4,302 shares of Palvella common stock, on June 17, 2026, July 15, 2026, and August 19, 2026, with reported aggregate sale values of $476,372.94, $642,191.37, and $654,791.07, respectively.

What transaction gives rise to the PVLA shares to be sold under Rule 144?

The shares to be sold are tied to a stock option exercise with Palvella Therapeutics as the issuer. The Form 144 indicates the method of acquisition as “Stock Option Exercise” and the form of payment as cash.

Who is acting as broker and signatory in the PVLA Form 144 filing?

The broker is Piper Sandler & Co, based in Minneapolis. The Form 144 is signed by Alex Johnson, a duly authorized representative of Piper Sandler Corporate & Venture Services, acting as attorney-in-fact for Kathleen Goin.

On which market are the PVLA shares in this Form 144 expected to trade?

The Form 144 identifies the trading market as Nasdaq for the Palvella Therapeutics, Inc. common stock covered by the proposed 4,302-share Rule 144 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:31 PM Accepted by SEC EDGAR 09/16/2026 - 04:31 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001912570
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PALVELLA THERAPEUTICS, INC.
SEC File Number	001-37471
Address of Issuer	353 W. LANCASTER AVENUE SUITE 200 WAYNE PENNSYLVANIA 19087
Phone	(484) 253-1461
Name of Person for Whose Account the Securities are To Be Sold	Goin Kathleen
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Piper Sandler & Co Inc 350 N 5th St Ste 1000 Minneapolis MN 55401	4302	650548.44	14408407	09/16/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/16/2026	Stock Option Exercise	Issuer			4302	09/16/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kathleen Goin C/O Palvella Therapeutics Inc 353 W Lancaster Ave Ste 200 Wayne PA 19087	Common Stock	06/17/2026	4302	476372.94
Kathleen Goin C/O Palvella Therapeutics Inc 353 W Lancaster Ave, Ste 200 Wayne PA 19087	Common Stock	07/15/2026	4302	642191.37
Kathleen Goin C/O Palvella Therapeutics Inc 353 W Lancaster Ave Ste 200 Wayne PA 19087	Common Stock	08/19/2026	4302	654791.07

144: Remarks and Signature

Remarks
Date of Notice	09/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Alex Johnson, a duly authorized representative of Piper Sandler & Co Corporate & Venture Services FA, as attorney-in-fact for Kathleen Goin
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)